Search Bar & Filters
Found 4 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the drug LXE408 in people with chronic Chagas disease who do not have severe organ dysfunction. This phase 2, randomized, participant- and investigator-blinded study compares LXE408 to placebo and the standard treatment benznidazole. The goal is to assess the drugs ability to clear or reduce parasites in the blood, as well as its safety, tolerability, pharmacokinetics, and pharmacodynamics. Participants are assigned to one of four groups LXE408 for 28 days, LXE408 for 14 days followed by placebo for 14 days, placebo for 28 days, or benznidazole for 60 days. The study involves oral administration of these treatments in a parallel group design. The treatment period is followed by monitoring to evaluate the effects and parasite clearance over time. During the study, participants undergo PCR testing at months 2, 4, 6, and 12 to check for sustained parasitological clearance. Other assessments include monitoring adverse events, blood drug levels at various days during treatment, and serology tests at months 6 and 12. The study also tracks participant health for up to 48 months to observe long-term outcomes and safety. Total participation may last several years including treatment and follow-up.
Actively Recruiting
Researchers are conducting a combined phase 2b and phase 3 clinical trial to study CSL300 Clazakizumab in adults with end stage kidney disease ESKD who are undergoing maintenance dialysis. The study aims to find the right dose of CSL300 and then evaluate its effects on cardiovascular outcomes and safety in people with systemic inflammation and either atherosclerotic cardiovascular disease ASCVD or diabetes. This multicenter, randomized, double-blind, placebo-controlled trial is designed to provide detailed information on the drugs impact and risks. The study is divided into two parts. Part 1 phase 2b focuses on identifying the optimal dose of CSL300 compared to a placebo over 12 weeks. Part 2 phase 3 assesses the efficacy and safety of CSL300 versus placebo on cardiovascular events such as cardiovascular death or heart attack over approximately 5 years. Participants receive intravenous doses of CSL300 or placebo. The placebo matches the CSL300 product minus the active ingredient. Participants will be monitored through regular assessments including blood tests to measure markers of inflammation like high-sensitivity C-reactive protein hs-CRP, other blood components, and drug levels. The trial tracks cardiovascular events and safety outcomes over the study period. The research team will also observe changes in several blood markers related to inflammation and cardiovascular health. The total follow-up may last up to about five years to fully capture long-term effects and safety.
Actively Recruiting
Researchers are investigating the long-term safety and tolerability of inclisiran in participants with heterozygous or homozygous familial hypercholesterolemia HeFH or HoFH who have previously completed specific pediatric ORION studies. This open-label, single arm, multicenter extension study aims to provide continued access to inclisiran treatment while monitoring its effects over an extended period. Participants who completed the ORION-16 or ORION-13 studies receive a fixed dose of inclisiran sodium 300 mg in solution form. Those who completed ORION-19 or ORION-20 receive inclisiran doses adjusted based on their body weight. The study involves ongoing administration of inclisiran to assess long-term treatment outcomes. During the study, participants are monitored for adverse events and serious adverse events from the first day up to approximately 1080 days. Researchers measure changes in LDL cholesterol levels compared to baseline from the previous studies. Participants will have regular visits and assessments to track safety, tolerability, and lipid changes throughout the study duration, which may last up to nearly three years.
Actively Recruiting
Researchers are evaluating whether the drug zilebesiran can reduce major cardiovascular events such as cardiovascular death, nonfatal heart attacks, strokes, or heart failure in adults with hypertension that is not well controlled and who have either established cardiovascular disease or are at high risk for it. This is a phase 3, randomized, double-blind, placebo-controlled study that will continue until a targeted number of cardiovascular events have occurred. Participants will receive either 300 mg of zilebesiran or a placebo by subcutaneous injection every six months, in addition to their standard antihypertensive medications, which must include a thiazide, thiazide-like, or loop diuretic. The study involves two parallel groups one receiving the active drug and the other receiving placebo, both as add-on therapies to current treatment. During the trial, participants will be regularly monitored for cardiovascular outcomes over approximately five years. The main measurement is the time to the first occurrence of a composite endpoint including cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or heart failure events requiring hospitalization or urgent visits. Blood pressure changes at six months and other cardiovascular outcomes will also be assessed. Safety and effectiveness will be closely observed throughout the study period.